Polycythemia Vera vs. Essential Thrombocythemia: Key Differences

Polycythemia vera (PV) and essential thrombocythemia (ET) are both chronic blood cancers that arise from the bone marrow, but they push blood cell production in different directions: PV drives an overproduction of red blood cells, while ET primarily overproduces platelets. Both fall under the umbrella of myeloproliferative neoplasms and share a common genetic thread in the JAK2 mutation, yet their day-to-day symptoms, complication profiles, and long-term trajectories can look quite different. Telling them apart matters because the wrong diagnosis can lead to the wrong treatment targets.

What PV and ET Actually Are

The World Health Organization classifies both PV and ET as BCR-ABL-negative myeloproliferative neoplasms, a family of diseases in which the bone marrow cranks out too many blood cells without the usual stop signals.¹ William Dameshek first grouped these conditions together in 1951, reasoning that a shared, self-perpetuating overproduction of multiple blood cell lines tied them together.² That intuition held up: more than half a century later, the discovery of the JAK2V617F mutation confirmed a molecular link between PV, ET, and primary myelofibrosis.

In PV, the dominant problem is too many red blood cells. The rising red cell mass thickens the blood, increasing viscosity and making clots more likely. In ET, the hallmark is a sustained, high platelet count. Platelets are the cell fragments responsible for clotting, so having far too many of them creates its own set of vascular risks. Both diseases can also push up white blood cell counts, and both carry a long-term risk of evolving into myelofibrosis or, more rarely, acute leukemia. But the proportions, the timelines, and the clinical flavor of each disease differ in ways that affect how doctors manage them.

The Genetic Landscape

PV is almost synonymous with the JAK2 mutation. Virtually all PV patients carry either the classic JAK2V617F mutation or, in a small minority, a mutation in JAK2 exon 12. ET has a wider mutational spectrum: patients may carry mutations in JAK2, the thrombopoietin receptor gene MPL, or the calreticulin gene CALR.³ A small group of ET patients test negative for all three, so-called “triple-negative” cases.

Even when ET and PV share the same JAK2V617F mutation, they differ in how much of the mutant gene is present. In a study of ET patients carrying JAK2V617F, the median mutant allele ratio was about 24%, far lower than the roughly 52% seen in PV patients.⁴ This allele burden difference helps explain why PV tends to be a more “aggressive” phenotype: a higher proportion of mutant cells means a stronger growth signal and more pronounced red cell overproduction. Some ET patients with rising JAK2 allele burdens over time may actually evolve into a PV phenotype, a transition that researchers are now studying prospectively.⁵

Which mutation an ET patient carries has real clinical consequences. CALR-mutated ET patients tend to have a lower risk of blood clots compared to those with JAK2 mutations. But there is a catch: a study from the Weill Cornell Myeloproliferative Neoplasms Center found that CALR-mutated ET patients had a significantly higher risk of progressing to myelofibrosis, with a 20-year myelofibrosis-free survival of just 48% for CALR-mutated disease versus 87% for JAK2-mutated ET. In multivariable analysis, CALR-mutated ET was linked to more than an 11-fold increased risk of post-ET myelofibrosis compared to JAK2-mutated disease.⁶ This finding challenges the common assumption that CALR-mutated ET is simply “lower risk” across the board.

Beyond the three driver mutations, additional mutations in genes like TET2, ASXL1, and DNMT3A appear to influence how both diseases behave over time. Patients whose molecular profiles evolve, picking up new mutations in these epigenetic regulators, are more likely to experience adverse outcomes or phenotypic shifts such as the ET-to-PV transition.⁵

How They Feel Different Day to Day

Some symptoms overlap heavily between PV and ET. Both can cause fatigue, headaches, dizziness, and numbness or tingling in the hands and feet. A cross-sectional study of patients with PV and ET in Korea found that fatigue, disease duration, numbness and tingling, bone pain, fever, weight loss, and abdominal discomfort all significantly influenced quality of life across both diseases.⁷ A larger international survey of over 1,100 PV and ET patients found that symptom clusters varied in ways that did not always track neatly with which diagnosis a person had, suggesting real overlap in how these diseases are experienced.⁸

That said, PV has a few signature symptoms that set it apart. The most distinctive is aquagenic pruritus, an intense itching triggered by contact with water at any temperature. About 40% of PV patients experience this.⁹ A large German survey painted an even more striking picture: out of 441 PV patients analyzed, roughly two-thirds reported aquagenic pruritus, and in most of those cases the itching started an average of about three years before the PV diagnosis was even made. It tends to hit the trunk and upper limbs hardest, and about 15% of sufferers described it as unbearable.¹⁰ Only rarely did this symptom prompt a hematology referral, which is a missed opportunity since it can be an early red flag for undiagnosed PV.

PV patients also tend to have a ruddy or reddish complexion because of their elevated red cell mass, and they are more prone to splenomegaly (an enlarged spleen) because the spleen works overtime filtering the excess blood cells. ET patients can develop splenomegaly too, but it is generally less pronounced.

Vascular Complications and Thrombosis

Both PV and ET raise the risk of abnormal blood clotting, but the mechanisms have different emphases. In PV, the elevated red cell mass directly increases whole blood viscosity, and this viscosity is what drives many of the vascular complications: microvascular circulatory problems, erythromelalgia (a painful burning and redness in the hands or feet), atypical transient cerebral ischemic events, and major arterial and venous thromboses.¹¹

In ET, the clotting story centers more on the platelets themselves. Overactive, hypersensitive platelets can spontaneously aggregate in small blood vessels, producing a spectrum of microvascular symptoms: tingling sensations, erythromelalgia, transient visual disturbances, and brief episodes of cerebral or coronary ischemia.¹² Erythromelalgia occurs in both diseases, but it is especially characteristic of ET and responds well to low-dose aspirin.

Splanchnic vein thrombosis, meaning clots in the veins draining the liver, spleen, or intestines, is a particularly notable complication in both PV and ET. It can sometimes be the very first sign that leads to a diagnosis. A large registry study of over 3,700 PV and ET patients found that those who presented with splanchnic vein thrombosis had a significantly higher risk of death, further venous clots, and major bleeding compared to patients without it.¹³

The Bleeding Paradox at Extreme Platelet Counts

Here is something that catches people off guard: extremely high platelet counts in ET (and, less commonly, in PV) can actually cause bleeding rather than clotting. When the platelet count climbs above roughly 1,000 × 10⁹/L, the body starts losing the large and intermediate von Willebrand factor multimers that are essential for normal clotting. This creates an acquired form of von Willebrand disease. The clotting risk that dominated at moderately elevated platelet counts gives way to a spontaneous bleeding tendency, typically appearing at mean platelet counts around 2,000 × 10⁹/L.¹⁴ This paradox is clinically important because giving aspirin to someone with extreme thrombocytosis and acquired von Willebrand disease can actually worsen bleeding. Clinicians often check von Willebrand factor levels before starting antiplatelet therapy in patients with very high counts.

How Thrombosis Risk Is Stratified Differently

Both PV and ET use age and thrombosis history as the backbone of risk assessment. Being older than 60 or having had a prior clot puts you in the high-risk category for both diseases. But beyond that, the details diverge.

For ET, an international prognostic scoring system called IPSET-thrombosis was developed and validated in a study of over 1,200 patients. It uses four factors: age over 60, prior thrombosis, cardiovascular risk factors like hypertension or diabetes, and JAK2V617F positivity. The model sorts patients into three risk tiers. Low-risk patients had a thrombosis rate of about 1% per year, intermediate-risk patients about 2.4% per year, and high-risk patients about 3.6% per year.¹⁵ JAK2V617F positivity carried a particularly strong weight in this model, assigned two points out of a possible six.

For PV, risk stratification has traditionally been simpler: the same two conventional factors (age over 60, prior thrombosis) define low versus high risk. However, experts have argued that maintaining a hematocrit below 45% and the absence of elevated white blood cell counts should be factored in for PV, while ET stratification could be refined by considering JAK2 status, CALR positivity, absence of leukocytosis, and absence of cardiovascular risk factors.¹⁶ These refined approaches have not fully replaced the conventional two-tier system in routine practice, but they reflect the growing recognition that a one-size-fits-all model misses meaningful differences.

Long-Term Progression

Both diseases can transform into myelofibrosis, a condition in which scar tissue gradually replaces the bone marrow and blood cell production falters. However, the rates differ. A literature review of published data found that post-PV myelofibrosis occurred in roughly 5–6% of patients at 10 years and 6–14% at 15 years, while post-ET myelofibrosis rates were somewhat lower at about 1–5% at 10 years and 4–11% at 15 years.¹⁷ The risk factors for transformation differ too. For PV, higher JAK2V617F allele burden, older age, elevated white blood cell count, existing reticulin fibrosis, and an enlarged spleen all increase the risk. For ET, the absence of JAK2V617F, older age, anemia, leukocytosis, and the presence of ASXL1 mutations are all risk factors.¹⁷

The risk of blast transformation, meaning progression to acute leukemia, is generally low for both diseases but tends to be somewhat higher in PV than in ET. Either transformation dramatically changes the prognosis and the treatment approach.

Treatment Differences

Treatment reflects the different biology of each disease. In PV, the first-line intervention for virtually every patient is phlebotomy, the periodic removal of blood to keep the hematocrit under control (the target is generally below 45%). Low-dose aspirin is standard alongside phlebotomy. For high-risk PV patients, cytoreductive drugs like hydroxyurea (hydroxycarbamide) are added to suppress marrow overproduction. When patients cannot tolerate or do not respond to hydroxyurea, the JAK inhibitor ruxolitinib has shown clear benefits: in a pivotal trial, ruxolitinib was superior to standard therapy for controlling the hematocrit, reducing spleen size, and improving symptoms. Hematocrit control was achieved in 60% of ruxolitinib-treated patients compared to 20% on standard therapy, and about 38% had a meaningful reduction in spleen volume compared to 1% on standard therapy.¹⁸

In ET, many low-risk patients need nothing beyond observation and possibly low-dose aspirin. (This is a real difference from PV, where phlebotomy is essentially universal.) High-risk ET patients typically receive hydroxyurea to lower platelet counts and reduce clotting risk. Anagrelide is another option, though it acts specifically on platelet production rather than broadly suppressing the marrow. For ET patients who are refractory to or intolerant of hydroxyurea, ruxolitinib has been investigated and shown some clinical benefit, particularly for symptom control, but it has not demonstrated the same clear superiority it has in PV. In the MAJIC-ET trial, ruxolitinib outperformed best available therapy mainly in terms of symptom relief rather than hard endpoints.¹⁹ This means the treatment toolkit for ET is somewhat more limited than for PV, and newer therapies remain an area of active research.

Pregnancy Considerations

ET is the most commonly encountered MPN during pregnancy, in part because it can affect younger women. It generally carries the most favorable prognosis of the MPNs during gestation. PV, by contrast, is associated with higher thrombotic risk in pregnancy, largely because of erythrocytosis and the resulting hyperviscosity.²⁰ Pregnant patients with PV are more likely to need treatment with aspirin and postpartum anticoagulation with low-molecular-weight heparin compared to those with ET.²¹

For both diseases, pregnancy requires close hematology and obstetric co-management. Hydroxyurea is avoided during pregnancy due to potential teratogenicity, so interferon-alpha is the preferred cytoreductive agent when one is needed. The risks of placental insufficiency and miscarriage exist for both conditions, but the general expectation is that with careful monitoring and appropriate antithrombotic therapy, many women with either PV or ET can have successful pregnancies.

When Diagnosis Gets Tricky

One of the genuine headaches in hematology is distinguishing between JAK2-mutated ET and so-called “masked” PV, a form of polycythemia vera in which the hemoglobin and hematocrit levels have not yet risen above the traditional diagnostic thresholds. The 2016 WHO classification update specifically addressed this, lowering the hemoglobin cutoffs for PV diagnosis and emphasizing bone marrow biopsy findings to help separate the two conditions.¹

This matters because a patient labeled as having ET when they actually have masked PV may not receive phlebotomy, and failing to control the hematocrit means leaving a treatable thrombotic risk factor unaddressed. The bone marrow biopsy plays a key role here: PV typically shows a hypercellular marrow with expansion of all three cell lines (red cells, white cells, and platelets), while ET marrow characteristically shows large, mature megakaryocytes with less pronounced expansion of other lines. But these distinctions can be subtle, and pathologist interpretation adds a degree of subjectivity to what is supposed to be a clear-cut classification.

Molecular Research on Megakaryocyte Biology in ET

ET research has increasingly focused on what goes wrong at the level of the megakaryocyte, the bone marrow cell that gives rise to platelets. Recent work has identified specific molecular regulators of megakaryocyte differentiation that behave abnormally in ET. A circular RNA called circ_0014614 was found to be significantly under-expressed in the bone marrow of ET patients. When researchers experimentally increased this RNA’s levels in bone marrow cells, it slowed both the proliferation and the differentiation of those cells into megakaryocytes.²² This kind of finding is still early-stage and a long way from the clinic, but it opens the door to understanding ET at a level that could eventually lead to more targeted therapies rather than the blunt cytoreductive approaches currently in use. PV research, by contrast, has been more focused on the JAK2 pathway itself, which already has a targeted drug (ruxolitinib) in clinical use. The two diseases, in other words, are not just clinically distinct but are also pulling researchers in different scientific directions.